For hospitals and study teams
Emtrial matches inclusion and exclusion criteria against approved clinical data sources. The study team receives potential matches for pre-screening and reviews every one of them.
4,000 of 4,000 records100%
Every record is given one of three states: met, information missing, or not met. Missing information stays open and never counts as an exclusion.
Emtrial uses approved EHR data, laboratory results, and clinical documents.
Review the AI assessment for each criterion. Click a source to see the information behind it.
12 Sep 2026
Follow-up visit: The patient walks daily, manages shopping and light housework independently, and continues office work. Jogging and heavy gardening are no longer possible due to rapid fatigue.
Inferred from the described activity level: ECOG 1. The study team needs to confirm this assessment.
12 Sep 2026
Antibiotic treatment started following a respiratory infection. Clinical improvement. Reassessment of infection status is pending.
Clarify the current infection status and treatment requirement. The exclusion criterion remains unresolved.
As of 14 Sep 2026
The approved medication data records systemic antibiotic treatment. No treatment end date is documented.
Clarify the current infection status and treatment requirement. The exclusion criterion remains unresolved.
As of 14 Sep 2026
The two latest approved eGFR results are dated 27 Aug 2026 and 12 Sep 2026.
The 16-day interval meets the timing requirement. Both measurements are below the required minimum.
The study-team workload
Three bottlenecks from published studies. The figures describe the cited settings and are not Emtrial performance claims.
Structured EHR data
overall completeness for recruitment pre-screening
Beyond manual search
additional patients included after an electronic recruitment report
Staffing constraints
of respondents cited limited human resources as a recruitment barrier
Sources and method: Köpcke et al., BMC Medical Informatics and Decision Making (2013) · five German university hospitals Köpcke et al., International Journal of Medical Informatics (2013) · one German study site Straube et al., Frontiers in Oncology (2017) · one German university hospital
The local study team reviews potential matches. Sponsors and CROs receive only aggregate information approved by the hospital.
Hospital-controlled environment
Will be shared
Stays inside the hospital
Limited external view
May leave after hospital approval
No patient records or individual matching results
We agree the specific measures with your IT and data protection teams.
Designed to run in the hospital-controlled environment. Matching and its results stay in your hospital’s systems.
Designed around GDPR purpose limitation and data minimisation: data is used only to match against a study, and your hospital decides which sources Emtrial draws on.
Designed for role-based access: only authorised members of the study team see potential matches and their sources.
Designed for audit logs that record who viewed which data and what was reviewed or released.
Common questions
Question not listed?Write to us
With clinical data sources that your institution approves. These include EHR data, laboratory systems, and clinical documents such as clinical notes and reports.
No. Emtrial searches the approved data and brings together the information for every criterion. Your study team reviews every potential match and decides on the next steps.
Every assessment of a criterion points to its source, for example a clinical note or a dated laboratory value. One click shows the underlying information.
Missing information is marked as open and is not treated as exclusion. Your team sees what is missing and can follow up on exactly that point.
In the hospital-controlled environment. Patient-level data and matching results remain within your hospital’s controlled systems. Emtrial is designed for role-based access and traceable logs.
With a conversation about your current search, the available data sources, and your requirements. IT, data protection, and the study team should be involved early. One possible start is a limited pilot with a single trial.
